| Study NΘ (% CRC) Rating | Study Design | Intervention Period | Intervention | Median Age (Range) | Previous Resection % | Median ECOG Score (Range) | Previous Local Hepatic Therapy % |
|---|---|---|---|---|---|---|---|
| Martin et al., 201286,a 24 (100) Fair | Retrospective case series | 02/2005–02/2009 | RE with Y90 via hepatic artery catheter infusion | 63 (35–83) | NR | NR | NR |
| Kucuk et al., 201184 78 (44.9) Fair | Retrospective case series | 06/2006–10/2010 | SIRT with Y90 via hepatic artery catheter under intermittent fluoroscopic visualization | Mean: 62.4 | 2.6 | NR | RFA: 7.7 Chemoembolization: 2.6 |
| Aliberti et al., 201190 82 (100) Good | Retrospective case series | 12/2005–09/2011 | TACE with irinotecan (100–2000 mg) in DC Beads (2–4 ml of beads) | 61.8 (46–82) | NR | 1 (0–2) | NR |
| Martin et al., 201175 55 (100) Good | Prospective case series | 10/2006–08/2008 | Intervention: TACE with DEB; Drug: irinotecan; Dose: median 185 mg, range 150–650 mg; Site: femoral or axillary artery | 60 (34–82) | 20 | 1 (0–2) | Ablation: 9.1 |
| Vautravers-Dewas et al., 201182 42 (66.7) Good | Retrospective case series | 07/2007–04/2009 | Intervention: SBRT; Radiation dose: 40 Gy and 45 Gy; Site: noninvasive | (23–82) | 51.1 | NR | RFA: 7 |
| Albert et al., 201163 121 (100) Fair | Retrospective case series | 03/1992–07/2008 | Intervention: TACE; Drug: mitomycin C, doxorubicin, cisplatin; Site: femoral artery | Mean: 61.9 | 17 | 0 (0 - ) | RFA: 17 |
| Nace et al., 201189 51 (100) Fair | Retrospective case series | 08/2002–05/2008 | RE with Y90 (delivery dose 50 Gy) via hepatic artery | 64 (37–83) | 23.5 | NR (0–1) | RFA: 21.6; HAI 9.8 |
| Stintzing et al., 201088 6 (100) Fair | Prospective case series | NR | Radiosurgery (24 Gy) for a single session | 66.5 (51–76) | 83.5 | NR | RFA: 17.6 |
| Nishiofuku et al., 201092 55 (100) Good | Retrospective case series | 04/2005–03/2008 | HAI of 5-FU (1000 mg/m2) via continuous 5-hour infusion once a week; Catheter inserted from left subclavian artery or right femoral artery | 62 (30–78) | 22 | 1 (0–3) | NR |
| Nishiofuku et al., 201092 55 (100) Good | Retrospective case series | 04/2005–03/2008 | HAI of 5-FU (1000 mg/m2) via continuous 5-hour infusion once a week; Catheter inserted from left subclavian artery or right femoral artery | 62 (30–78) | 22 | 1 (0–3) | NR |
| Cosimelli et al., 201066 50 (100) Good | Prospective case series | 05/2005–08/2007 | Intervention: RE; Drug: Y90; Site: hepatic artery | 67 (34–85) | 24 | 0 (0–3) | NR |
| Kim et al., 200971 9 (100) Good | Retrospective case series | 06/2004–12/2006 | Intervention: SBRT; Radiation dose: median 42 Gy, range 36–51 Gy; Site: noninvasive | 57 (35–74) | NR | NR (1–2) | NR |
| Cianni et al., 200965 41 (100) Fair | Retrospective case series | 02/2005–01/2008 | Intervention: RE; Y90 dose: mean 1.82 GBq; Site: hepatic artery | NR (33–77) | NR | 0.7 (0 - ) | TACE: 4.8; RFA or cryosurgical ablation: 19.5 |
| Mulcahy et al., 200976 72 (100) Good | Prospective case series | 2003–2007 | Intervention: RE; Y90 dose: median 118 Gy; Site: hepatic artery | 61 (54–86) | NR | 0 (0–2) | NR |
| Jakobs et al., 200891 41 (100) Fair | Retrospective case series | 10/2003–04/2007 | Intervention: RE; Y90 dose: mean 1.9 GBq (range 0.7–2.8 GBq). | NR | NR | NR | NR |
| Sato et al., 200878 137 (37.2) Fair | Prospective case series | 2002–2006 | Intervention: RE; Y90 dose: median 1.83 GBq, range 0.7–6.9 GBq, median 112.8 Gy, range 27–180 Gy; Site: hepatic artery | NR | NR | 0 (0–3) | Local hepatic therapy (unspecified): 16 |
| Vogl et al., 200883 55 (21.8) Fair | Retrospective case series | 2002–2006 | Intervention: HAI; Drug: mitomycin C, gemcitabine; Site: femoral artery | 63.5 (54–80) | NR | NR | NR |
| Hong et al., 200968 21 (100) Good | Retrospective case series | 01/2001–03/2006 | Intervention: TACE; Drug: cisplatin, doxorubicin, mitomycin C; Site: femoral artery | 67 (32–88) | 23 | NR | Cryosurgical ablation: 4.8, Radiation: 4.8, RFA: 9.5 |
| Intervention: RE; Y90 dose: median 112.9 Gy/tx, median 113.0 Gy/pt; Site: femoral artery | 67 (51–80) | 20 | NR | RFA: 6.7, TACE: 13.3 | |||
| Rowe et al., 200777 24 (29.2) Good | Retrospective case series | 07/2004–11/2005 | Intervention: RE; Y90 dose: median 103 Gy, range 41–145 Gy, median 1.8 GBq, range 1.5–2.0 GBq; Site: hepatic artery | 57 (53 – 68) | NR | 1 (0–2) | NR |
| Jiao et al., 200770 21 (47.6) Poor | Prospective case series | 06/2004 – NR | Intervention: RE; Y90 dose: mean 1.9 GBq, range 1.2–2.5 GBq; Site: femoral catheter or hepatic artery port | NR (40–75) | 31 | NR | RFA: 48 |
| Fiorentini et al., 200767 20 (100) Poor | Prospective case series | 11/2005 – ongoing (06/2007) | Intervention: TACE with DEB; Drug: irinotecan; Site: hepatic artery | NR | NR | 1 (0–2) | NR |
| Jakobs et al., 200669 68 (100) Good | Retrospective case series | 01/2000–06/2004 | Intervention: RFA; Site: percutaneous | (38–87) | 16 | NR | HAI: 3, TACE: 3 |
| Lewandowski et al., 200573 27 (100) Good | Prospective case series | 06/2001–12/2003 | Intervention: RE; Y90 dose: range 135–150 Gy; Site: lobar | 68 (54–86) | NR | 0 (0–2) | NR |
| Lim et al., 200574 30 (100) Poor | Prospective case series | 01/2002–03/2004 | Intervention: RE; Drug: Y90 | 61.7 (36–77) | NR | 0 (0 – 2) | NR |
CRC = colorectal cancer; DEB = drug-eluting bead; ECOG = Eastern Cooperative Oncology Group; GBq = Gigabecquerel; Gy = Gray; HAI = hepatic arterial infusion; Mets = Metastases; NR = not reported; RE = radioembolization; RFA = radiofrequency ablation; SBRT = stereotactic body radiation therapy; SIRT = selective internal radiotherapy; TACE = transarterial chemoembolization; tx = treatment; pt = patient; Y90 = Yttrium-90
Data on patient characteristics from this case series include patients with extrahepatic disease; information on outcomes is for patients with non-extrahepatic disease.
This N reflects the total number of patients enrolled in the study from any primary site. The percentage of CRC patients included in this report is presented in parentheses.
From: Results
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.